查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1603799

2030 年前列腺素琴酒市場預測：按產品類型、給藥途徑、分銷管道、應用和地區進行的全球分析

Prostaglandin Analogs Market Forecasts to 2030 - Global Analysis By Product Type, Route of Administration, Distribution Channel, Application and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2024 年全球琴酒類似物市場規模為 39 億美元，預計到 2030 年將達到 61 億美元，預測期內複合年成長率為 7.5%。

稱為前列腺素琴酒的合成物質複製了天然琴酒的作用，天然前列腺素是參與許多生理功能（例如發炎和平滑肌收縮）的脂質分子。這些類似物常用於眼科治療，特別是用於降低青光眼等疾病的眼內壓。

根據《藥理學前沿》發表的一項臨床研究，琴酒類似物 (PGA) 被認為是治療青光眼的一線藥物，最有效的長期治療是 0.03% 比Bimatoprost，其次是0.005% 比馬前列素。

眼科疾病盛行率上升

青光眼、高眼壓症和其他眼科疾病的盛行率不斷增加，推動了對琴酒類似物的需求。隨著世界人口老化，這些疾病的盛行率不斷增加，需要有效的治療方法。前列腺素琴酒能有效降低眼壓，使其成為許多眼科疾病的第一線藥物。疾病負擔的增加導致尋求治療的患者增加，從而推動了市場的成長。

高成本

名牌前列腺素琴酒的高成本可能會限制病患的使用和市場成長，特別是在新興市場。專利保護使製造商能夠為這些藥物爭取高價。研究開發、臨床試驗和監管核准成本均反映在最終產品成本中。對許多患者來說，長期使用這些藥物會帶來巨大的經濟負擔。這種成本障礙可能會導致一些患者選擇更便宜的替代治療。

擴展到新的治療領域

前列腺素琴酒不僅可用於青光眼和高眼壓症，還可用於其他治療領域。正在進行的研究正在調查其對乾眼、視網膜疾病和角膜癒合等疾病的有效性。這些藥物的發炎和神經保護特性使其成為各種眼科應用的有希望的候選藥物。如果新適應症開拓成功，市場將顯著擴大，並為製造商提供新的收入來源。

監管挑戰

眼科藥物嚴格的監管要求對市場成長構成威脅。獲得並維持前列腺素琴酒的核准既耗時又昂貴。監管變化、安全問題或不利事件可能導致市場退出或限制。上市後監測和藥物安全檢測要求增加了營運成本。對於這個市場上的製造商來說，應對不同地區複雜的監管環境是一個持續的挑戰。

COVID-19 的影響：

COVID-19 大流行以多種方式擾亂了琴酒類似物市場。封鎖和安全措施減少了患者定期看眼科醫生的次數，可能會延遲診斷和治療的開始。供應鏈中斷影響了製造和分銷。然而，這種流行病也可能加速遠端醫療在眼科照護中的採用，改善長期獲得處方和後續觀察的機會。隨著醫療保健系統的復甦，對眼保健服務的需求不斷成長可能會推動市場成長。

預計在預測期內外用藥物領域將是最大的

預計外用藥物領域將在預測期內獲得最大的市場佔有率。局部給藥（主要透過眼藥水）是琴酒類似物的主要給藥途徑。這種方法有幾個優點，包括直接給藥到目標部位、最小的全身吸收以及患者易於使用。局部製劑可以實現精確的劑量，並且比全身性治療的副作用更少。許多琴酒類似物眼藥水每天一次的便利性提高了患者的依從性。局部給藥系統的持續創新，例如無防腐劑配方和緩釋性技術，進一步支持了該領域的成長。

預計高眼壓領域在預測期內的複合年成長率最高。

預計高眼壓細分市場在預測期內將顯著成長。高眼壓的特徵是眼壓升高，但沒有視神經損傷或視野缺陷，代表著巨大的市場機會。琴酒類似物的早期療育可以有效控制眼壓並防止進展為青光眼。高眼壓已被認為是青光眼的危險因素，篩檢和開始治療的強度正在增加。隨著診斷技術的進步，更多的病例可以更早被發現。控制高眼壓的預防性方法預計將推動這一領域的快速成長。

比最大的地區

預計北美地區在預測期內將佔據最大的市場佔有率。該地區青光眼和高眼壓症發病率很高，而且人口老化。先進的醫療基礎設施和高額醫療支出擴大了這些藥物的取得範圍。主要市場參與者的強大影響力和持續的研究活動有助於保持市場領先地位。此外，優惠的青光眼治療報銷政策和保險範圍正在支持市場成長。

複合年成長率最高的地區：

預計亞太地區在預測期內將實現最高的複合年成長率。因素包括人口眾多且老化、眼科疾病率增加、醫療保健的普及。在中國和印度等國家，可支配收入的增加和中階的壯大使得先進的治療方法變得更便宜。政府為防治失明和改善眼部保健所做的努力正在創造有利的市場環境。人們對眼睛健康意識的提高和醫療保健基礎設施的擴大也有助於該地區的市場擴張。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場公司的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭標基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球琴酒類似物市場：依產品類型

  • 拉坦前列素
  • Bimatoprost
  • 曲伏前列素
  • 他氟前列素
  • 其他產品類型

第6章全球琴酒類似物市場：依給藥途徑

  • 外用
  • 口服
  • 注射

第7章全球琴酒類似物市場：按分銷管道

  • 醫院藥房
  • 零售藥房
  • 專業藥房
  • 線上交付

第8章全球琴酒類似物市場：按應用

  • 青光眼治療
  • 促進睫毛生長
  • 眼壓升高
  • 乾眼症
  • 保護胃
  • 其他應用

第9章全球琴酒類似物市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第10章 主要進展

  • 合約、夥伴關係、合作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第11章 公司概況

  • Pfizer Inc.
  • Allergan plc
  • Novartis AG
  • Bayer AG
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Ocular Therapeutix, Inc.
  • Aerie Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Yonsung Fine Chemicals
  • Everlight Chemical
  • Piramal Enterprises
  • Bio-Techne Corporation
  • Mironova Labs
  • Chirogate
  • Cepia, LLC
  • Johnson Matthey
Product Code: SMRC27821

According to Stratistics MRC, the Global Prostaglandin Analogs Market is accounted for $3.9 billion in 2024 and is expected to reach $6.1 billion by 2030, growing at a CAGR of 7.5% during the forecast period. Synthetic substances called prostaglandin analogs replicate the actions of natural prostaglandins, which are lipid molecules involved in a number of physiological functions like inflammation and smooth muscle contraction. To reduce intraocular pressure in diseases like glaucoma, these analogs are frequently used in medical treatments, particularly in ophthalmology.

According to clinical research published in Frontiers in Pharmacology, prostaglandin analogs (PGAs) are considered the first-line treatment for glaucoma, with the most effective long-term therapy being 0.03% bimatoprost, followed by 0.005% latanoprost and 0.004% travoprost.

Market Dynamics:

Driver:

Rising prevalence of ophthalmic conditions

The increasing incidence of glaucoma, ocular hypertension, and other eye disorders is driving demand for prostaglandin analogs. As the global population ages, the prevalence of these conditions is growing, necessitating effective treatments. Prostaglandin analogs have become a first-line therapy for many ophthalmic issues due to their efficacy in lowering intraocular pressure. The rising disease burden is compelling more patients to seek treatment, fueling market growth.

Restraint:

High costs

The high costs associated with branded prostaglandin analog medications can limit patient access and market growth, especially in developing regions. Patent protection allows manufacturers to charge premium prices for these drugs. The expenses of research, development, clinical trials, and regulatory approvals are reflected in the final product costs. For many patients, the long-term use of these medications represents a significant financial burden. This cost barrier may lead some to opt for alternative, less expensive treatments.

Opportunity:

Expansion into new therapeutic areas

There is potential to expand the use of prostaglandin analogs beyond glaucoma and ocular hypertension into other therapeutic areas. Ongoing research is exploring their efficacy for conditions like dry eye disease, retinal disorders, and corneal healing. The anti-inflammatory and neuroprotective properties of these drugs make them promising candidates for various ophthalmic applications. Successful development of new indications would significantly expand the market and provide additional revenue streams for manufacturers.

Threat:

Regulatory challenges

Stringent regulatory requirements for ophthalmic medications pose a threat to market growth. Obtaining and maintaining regulatory approvals for prostaglandin analogs can be a lengthy and costly process. Changing regulations, safety concerns, or adverse events could lead to market withdrawals or restrictions. Post-marketing surveillance and pharmacovigilance requirements add to operational costs. Navigating the complex regulatory landscape across different regions presents ongoing challenges for manufacturers in this market.

Covid-19 Impact:

The COVID-19 pandemic disrupted the prostaglandin analogs market in several ways. Lockdowns and safety measures led to reduced patient visits for routine eye care, potentially delaying diagnoses and treatment initiations. Supply chain disruptions affected manufacturing and distribution. However, the pandemic also accelerated the adoption of telemedicine for ophthalmic care, potentially improving long-term access to prescriptions and follow-ups. As healthcare systems recover, pent-up demand for eye care services may drive market growth.

The topical segment is expected to be the largest during the forecast period

The topical segment is predicted to secure the largest market share throughout the forecast period. Topical administration, primarily through eye drops, is the dominant route for prostaglandin analogs. This method offers several advantages, including direct delivery to the target site, minimal systemic absorption, and ease of use for patients. Topical formulations allow for precise dosing and reduced side effects compared to systemic treatments. The convenience of once-daily application for many prostaglandin analog eye drops improves patient compliance. Ongoing innovations in topical drug delivery systems, such as preservative-free formulations and sustained-release technologies, are further driving the growth of this segment.

The ocular hypertension segment is expected to have the highest CAGR during the forecast period

The ocular hypertension segment is projected to witness substantial growth during the projection period. Ocular hypertension, characterized by elevated intraocular pressure without optic nerve damage or visual field loss, represents a significant market opportunity. Early intervention with prostaglandin analogs can effectively manage intraocular pressure and potentially prevent progression to glaucoma. The growing awareness of ocular hypertension as a risk factor for glaucoma is leading to increased screening and treatment initiation. As diagnostic technologies improve, more cases are being identified at earlier stages. The preventive approach to managing ocular hypertension is expected to drive rapid growth in this segment.

Region with largest share:

The North America region is projected to account for the largest market share during the forecast period. The region has a high prevalence of glaucoma and ocular hypertension, coupled with an aging population. Advanced healthcare infrastructure and high healthcare spending enable greater access to these medications. Strong presence of key market players and ongoing research activities contribute to market leadership. Additionally, favorable reimbursement policies and insurance coverage for glaucoma treatments support market growth.

Region with highest CAGR:

The Asia Pacific region is projected to achieve the highest CAGR during the forecast period. Factors driving this include a large and aging population, increasing prevalence of eye disorders, and improving healthcare access. Rising disposable incomes and an expanding middle class in countries like China and India are enabling greater affordability of advanced treatments. Government initiatives to combat blindness and improve eye care are creating a favorable market environment. Growing awareness of eye health and expanding healthcare infrastructure are also contributing to market expansion in this region.

Key players in the market

Some of the key players in Prostaglandin Analogs Market include Pfizer Inc., Allergan plc, Novartis AG, Bayer AG, GlaxoSmithKline plc, Merck & Co., Inc., Santen Pharmaceutical Co., Ltd., Ocular Therapeutix, Inc., Aerie Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Yonsung Fine Chemicals, Everlight Chemical, Piramal Enterprises, Bio-Techne Corporation, Mironova Labs, Chirogate, Cepia, LLC, and Johnson Matthey.

Key Developments:

In October 2024, GSK plc and Chimagen Biosciences (Chimagen), a privately held biotechnology company, announced an agreement for GSK to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager (TCE), from Chimagen for $300 million upfront. GSK plans to develop and commercialise CMG1A46 with a focus on B cell-driven autoimmune diseases, such as systemic lupus erythematosus (SLE) and lupus nephritis (LN), with potential to expand into related autoimmune diseases.

In September 2024, Novartis announced that the US Food and Drug Administration (FDA) has approved Kisqali(R) (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of people with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) stage II and III early breast cancer (EBC) at high risk of recurrence, including those with node-negative (N0) disease.

In November 2023, Santen received European Commission approval for Catiolanze(R), a cationic emulsion of latanoprost 50μg/mL. This preservative-free prostaglandin analog is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The approval follows positive results from a Phase III clinical trial that demonstrated non-inferiority to traditional latanoprost solutions and improved outcomes for patients with Ocular Surface Disease (OSD).

Product Types Covered:

  • Latanoprost
  • Bimatoprost
  • Travoprost
  • Tafluprost
  • Other Product Types

Route of Administrations Covered:

  • Topical
  • Oral
  • Injectable

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Specialty Pharmacies
  • Online Distribution

Applications Covered:

  • Glaucoma Treatment
  • Lash Growth Enhancement
  • Ocular Hypertension
  • Dry Eye Disease
  • Gastric Protection
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Prostaglandin Analogs Market, By Product Type

  • 5.1 Introduction
  • 5.2 Latanoprost
  • 5.3 Bimatoprost
  • 5.4 Travoprost
  • 5.5 Tafluprost
  • 5.6 Other Product Types

6 Global Prostaglandin Analogs Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Topical
  • 6.3 Oral
  • 6.4 Injectable

7 Global Prostaglandin Analogs Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital Pharmacies
  • 7.3 Retail Pharmacies
  • 7.4 Specialty Pharmacies
  • 7.5 Online Distribution

8 Global Prostaglandin Analogs Market, By Application

  • 8.1 Introduction
  • 8.2 Glaucoma Treatment
  • 8.3 Lash Growth Enhancement
  • 8.4 Ocular Hypertension
  • 8.5 Dry Eye Disease
  • 8.6 Gastric Protection
  • 8.7 Other Applications

9 Global Prostaglandin Analogs Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Pfizer Inc.
  • 11.2 Allergan plc
  • 11.3 Novartis AG
  • 11.4 Bayer AG
  • 11.5 GlaxoSmithKline plc
  • 11.6 Merck & Co., Inc.
  • 11.7 Santen Pharmaceutical Co., Ltd.
  • 11.8 Ocular Therapeutix, Inc.
  • 11.9 Aerie Pharmaceuticals, Inc.
  • 11.10 Sun Pharmaceutical Industries Ltd.
  • 11.11 Yonsung Fine Chemicals
  • 11.12 Everlight Chemical
  • 11.13 Piramal Enterprises
  • 11.14 Bio-Techne Corporation
  • 11.15 Mironova Labs
  • 11.16 Chirogate
  • 11.17 Cepia, LLC
  • 11.18 Johnson Matthey

List of Tables

  • Table 1 Global Prostaglandin Analogs Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Prostaglandin Analogs Market Outlook, By Product Type (2022-2030) ($MN)
  • Table 3 Global Prostaglandin Analogs Market Outlook, By Latanoprost (2022-2030) ($MN)
  • Table 4 Global Prostaglandin Analogs Market Outlook, By Bimatoprost (2022-2030) ($MN)
  • Table 5 Global Prostaglandin Analogs Market Outlook, By Travoprost (2022-2030) ($MN)
  • Table 6 Global Prostaglandin Analogs Market Outlook, By Tafluprost (2022-2030) ($MN)
  • Table 7 Global Prostaglandin Analogs Market Outlook, By Other Product Types (2022-2030) ($MN)
  • Table 8 Global Prostaglandin Analogs Market Outlook, By Route of Administration (2022-2030) ($MN)
  • Table 9 Global Prostaglandin Analogs Market Outlook, By Topical (2022-2030) ($MN)
  • Table 10 Global Prostaglandin Analogs Market Outlook, By Oral (2022-2030) ($MN)
  • Table 11 Global Prostaglandin Analogs Market Outlook, By Injectable (2022-2030) ($MN)
  • Table 12 Global Prostaglandin Analogs Market Outlook, By Distribution Channel (2022-2030) ($MN)
  • Table 13 Global Prostaglandin Analogs Market Outlook, By Hospital Pharmacies (2022-2030) ($MN)
  • Table 14 Global Prostaglandin Analogs Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
  • Table 15 Global Prostaglandin Analogs Market Outlook, By Specialty Pharmacies (2022-2030) ($MN)
  • Table 16 Global Prostaglandin Analogs Market Outlook, By Online Distribution (2022-2030) ($MN)
  • Table 17 Global Prostaglandin Analogs Market Outlook, By Application (2022-2030) ($MN)
  • Table 18 Global Prostaglandin Analogs Market Outlook, By Glaucoma Treatment (2022-2030) ($MN)
  • Table 19 Global Prostaglandin Analogs Market Outlook, By Lash Growth Enhancement (2022-2030) ($MN)
  • Table 20 Global Prostaglandin Analogs Market Outlook, By Ocular Hypertension (2022-2030) ($MN)
  • Table 21 Global Prostaglandin Analogs Market Outlook, By Dry Eye Disease (2022-2030) ($MN)
  • Table 22 Global Prostaglandin Analogs Market Outlook, By Gastric Protection (2022-2030) ($MN)
  • Table 23 Global Prostaglandin Analogs Market Outlook, By Other Applications (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.